NO synthase inhibitor. An NMDA antagonist acting as a competitive inhibitor at the polyamine site.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 25 mM in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 270.31. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.7 mL||18.5 mL||36.99 mL|
|5 mM||0.74 mL||3.7 mL||7.4 mL|
|10 mM||0.37 mL||1.85 mL||3.7 mL|
|50 mM||0.07 mL||0.37 mL||0.74 mL|
References are publications that support the products' biological activity.
Doyle and Shaw (1998) Investigation of the actions and antagonist activity of some polyamine analogues in vivo. Br.J.Pharmacol. 124 386 PMID: 9641557
Reynolds (1990) Arcaine is a competitive antagonist of the polyamine site on the NMDA receptor. Eur.J.Pharmacol. 177 215 PMID: 2155812
Yokoi et al (1994) Structure-activity relationships of arginine analogues on nitric oxide synthase activity in the rat brain. Neuropharmacology 33 1261 PMID: 7532812
If you know of a relevant reference for Arcaine sulfate, please let us know.
View Related Products by Product Action
Keywords: Arcaine sulfate, supplier, Competitive, NMDA, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, NMDA, Receptors, NMDA, Receptors, Tocris Bioscience
Citations for Arcaine sulfate
Citations are publications that use Tocris products.
Currently there are no citations for Arcaine sulfate. Do you know of a great paper that uses Arcaine sulfate from Tocris? If so please let us know.
Reviews for Arcaine sulfate
There are currently no reviews for this product. Be the first to review Arcaine sulfate and earn rewards!
Have you used Arcaine sulfate?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.